The Jan. 28 warning applies to CovClear COVID-19 Rapid Antigen Test and the ImmunoPass COVID-19 Neutralizing Antibody Rapid Test.
Neither test has been authorized, cleared or approved by the FDA for use in the U.S. Empowered Diagnostics, the tests’ maker, issued a Class I recall for the tests, the most serious type.
The FDA said clinicians should consider retesting any patients given either rapid diagnostic test less than two weeks ago due to the risk of false results.
Learn more here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
